Status: Recruiting
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Guangzhou Medical UniversityUpdated: Jun 25, 2024Locations: 1
Eligibility criteria
Had accepted gene therapy before; [+7]